Fractyl Health, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Fractyl Health, Inc. operates as a pioneering metabolic therapeutics organization, dedicated to advancing novel solutions for the persistent challenges of type 2 diabetes and obesity. The company champions the Revita DMR System, an innovative outpatient procedural therapy designed to fundamentally address duodenal dysfunction. This condition, a pathological outcome stemming from diets rich in fats and sugars, is recognized as a key instigator of metabolic diseases in individuals. Through its distinct approach, Revita aims to durably modify the duodenum's role in metabolic regulation. Furthermore, Fractyl Health is developing Rejuva, an advanced gene therapy platform that utilizes a novel virus delivery mechanism targeting the pancreas. This platform is engineered to foster sustained remission in patients by enduringly modifying metabolic hormone function within pancreatic islet cells. The company, originally established as Fractyl Laboratories Inc. in 2010, rebranded to Fractyl Health, Inc. on June 9, 2021, and is based in Burlington, Massachusetts. Fractyl Health, Inc. recently completed an initial public offering in February 2024, listing on Nasdaq under the ticker symbol GUTS. The Revita DMR System, which has received FDA Breakthrough Device designation for type 2 diabetes and weight maintenance, is undergoing pivotal clinical studies, notably focusing on maintaining weight loss following GLP-1 therapy discontinuation. Early data from trials like REMAIN-1 indicates positive results for Revita in supporting weight management. The Rejuva gene therapy platform continues to progress, with candidates such as RJVA-001 having its first Clinical Trial Application module submitted in Europe, aiming for initial human studies and data reporting in 2026, while preclinical results for RJVA-002 demonstrate significant weight reduction in models of obesity. Fractyl Health's strategy emphasizes addressing the root physiological causes of these metabolic conditions, striving to shift treatment paradigms from chronic symptomatic management toward durable, disease-modifying interventions.
Fractyl Health Stock Up on Encouraging One-Year Revita Study Results
Fractyl Health, Inc. (GUTS) Discusses 1-Year REMAIN-1 Data Demonstrating Durable Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars
Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Fractyl Health Q1 Earnings Call Highlights
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference
Fractyl Health, Inc. (NASDAQ:GUTS) Receives $5.40 Average Price Target from Analysts
Scalable Biotech Manufacturing Unlocks a $14B Market
Fractyl Health Q4 Earnings Call Highlights
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026
Fractyl Health, Inc. (GUTS) Moves to Buy: Rationale Behind the Upgrade
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance